Modern Pharmaceutics for Cardiovascular Diseases

Dear Colleagues,

Observational studies have shown that cardiovascular diseases are the leading cause of mortality in the world, and it is estimated that disturbances such as ischemic heart disease and stroke account for approximately 80% of cardiovascular disease mortality. Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases.

 It is well known that recent advances in pharmaceutics made the development of new drugs for cardiovascular diseases, which are able to significantly improve the short- and long-term prognosis and to prevent premature deaths, possible. Thus, we are pleased to invite you to submit your original articles and/or review papers to this Special Issue which aims to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years.

In this Special Issue “Modern Pharmaceutics for Cardiovascular Diseases”, original research articles and reviews from both experimental and clinical studies are welcome. Research areas may include (but are not limited to) the following: modern pharmaceutics for heart failure, arterial hypertension, pulmonary embolism, pulmonary arterial hypertension, heart rhythm disturbances, ischemic heart disease, peripheral artery disease, deep venous thrombosis, cardiomyopathies, and atherosclerosis.

We look forward to receiving your contributions.

Dr. Ionut Tudorancea
Dr. Radu Iliescu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.